Japan considering intradermal seasonal influenza vaccine
Four companies developed the vaccine: Daiichi Sankyo; Kitasato Daiichi Sankyo Vaccine Co., Ltd.; Terumo; and Japan Vaccine. This collaboration was made as part of an agreement between Terumo and Daiichi Sankyo.
Terumo was responsible for creating the intradermal injection device, which makes it easier to administer the vaccine. This new method should ease patients' fear about receiving injected vaccines since it isn't as deep as vaccines administered to the hypodermis. The new device also lessens the chances of damaging peripheral blood vessels or nerves as the health care worker injects the vaccine into the subcutaneous tissue.
Daiichi Sankyo executives have voiced their commitment to further developments that will prevent the spread of seasonal influenza. They see the new vaccine as one of the best ways to achieve this goal. Daiichi also seeks to improve hygiene as the company continues to contribute to the vaccine industry.